Skip to main content
SpringerLink
Log in

Safety Signals Using Proportional Reporting Ratios from Company and Regulatory Authority Databases

  • Pharmacovigilance
  • Published:
Drug information journal : DIJ / Drug Information Association Aims and scope Submit manuscript

Abstract

Databases held by regulatory agencies and by pharmaceutical companies may be used to detect safety signals. We compared the utility of a company safety database with those from two large regulatory authority databases in assessing potential safety signals in order to understand how the different sources may be used. Proportional reporting ratios (PRRs) were calculated from the company database for historical events that had led to changes in prescribing information (PI) and were compared to PRRs calculated in external databases (the US Food and Drug Administration Freedom of Information database and the UK Adverse Drug Reactions On-line Information Tracking database). For most events there was agreement between all of the databases. For some selected historical events we have shown that if a company database is large enough and a wide range of therapeutic areas is covered then there is insignificant difference between PRRs calculated from the company database and larger external databases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Evans SJW. Pharmacovigilance: a science or fielding emergencies? Stat Med. 2000;19:3199–3209.

    Article  CAS  Google Scholar 

  2. Moore N. Thiessard F. Begaud B. The history of disproportionality measures (reporting odds ratio, proportional reporting rates) in spontaneous reporting of adverse drug reactions. Pharmacoepidemiol Drug Safety. 2005;14:285– 286.

    Article  Google Scholar 

  3. Evans SJW. Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Safety. 2001;10:483–486.

    Article  CAS  Google Scholar 

  4. Rothman KJ. Lanes S, Sacks ST. The reporting odds ratio and its advantages over proportional reporting ratio. Pharmacoepidemiol Drug Safety. 2004;13:519–523.

    Article  Google Scholar 

  5. van Puijenbroek E, Bate A, Leufkens HGM, et al. A comparison of measures of disproportionaiity for signal detection in spontaneous reporting systems for adverse drug reactions, Pharmacoepidemiol Drug Safety. 2002;11:3–10.

    Article  Google Scholar 

  6. Waller P. van Puijenbroek E, Egberts A, et al. The reporting odds ratio versus the proportional reporting ratio: “deuce.” Pharmacoepidemiol Drug Safety. 2004;13:525-526.

    Article  Google Scholar 

  7. Roux E. Thiessard F, Fourrier A. et al. Evaluation of statistical association measures for the automatic signal generation in pharmacovigilance. IEEE Trans Inf Technol Biomed. 2005;9(4):518–527.

    Article  Google Scholar 

  8. Almenoff J. Tonning JM, Gould L. et al. Perspectives in the use of data mining. Pharmacovigilance Drug Safety. 2005;28:981–1007.

    Article  CAS  Google Scholar 

  9. Strom BL, Kimmel SE, eds. Textbook of Pharma-coepidemiology. (Chichester, UK: Wiley & Sons: 2006.

    Google Scholar 

  10. Kilgour-Christie J, Czarnecki A. Simmons V. Proportional reporting ratio calculations from a pharmaceutical company database. Pharmacoepidemiol Drug Safety. 2001:10(Suppl 1):S159.

    Google Scholar 

  11. Kilgour-Chrislie J, Czarnecki A. Safety signals verified using PRRs on regulator) authority databases. Pharmacoepidemiol Drug Safety. 2002:11 (Suppl 1):S145–S146.

    Google Scholar 

  12. Rodriguez EM. Staffa JA, Graham DJ. The role of databases in drug postmarketing surveillance. Pharmacoepidemiol Drug Safety. 2001; 10:407–410.

    Article  CAS  Google Scholar 

  13. FDA Adverse Event Reporting System (AERS). Available at: http://www.fda.gov/cder/aers/default.htm. Accessed September 13, 2005.

  14. Wood SM, Coulson R. Adverse drug reactions online information tracking (ADROIT). Pharm Med. 1993:7:203–213.

    Google Scholar 

  15. Dean AD. Dean AJ, Dicker RC. Epi Info Version 5: A Word Processing. Database and Statistical Program for Epidemiology on Microcomputers. Atlanta, GA: Centers for Disease Control: 1990.

    Google Scholar 

  16. Medicines Control Agency. 2001, Available al: http://www.accenture.com/Countries/UK/Services/By_Subject/Infrastrueture_Outsourcing/Client_Succcsses/MedicinesEcommerce.htm. Accessed May 2, 2006.

Download references

Author information

Authors and Affiliations

  1. Global Product Safety, Eli Lilly & Co. Lilly Research Centre, GU20 6PH, Windlesham, Surrey, UK

    Andrzej Czarnecki MD, PhD, DSc & Simon Voss MB BS, FFPH, FFPM

Authors
  1. Andrzej Czarnecki MD, PhD, DSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Simon Voss MB BS, FFPH, FFPM
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrzej Czarnecki MD, PhD, DSc.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Czarnecki, A., Voss, S. Safety Signals Using Proportional Reporting Ratios from Company and Regulatory Authority Databases. Ther Innov Regul Sci 42, 205–210 (2008). https://doi.org/10.1177/009286150804200301

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1177/009286150804200301

Key Words

Search

Navigation